<DOC>
	<DOCNO>NCT00625339</DOCNO>
	<brief_summary>This randomize , open-labelled , prospective 96-week study compare antiviral efficacy safety switch entecavir 0.5mg QD lamivudine versus maintain lamivudine 100mg QD treatment CHB patient currently receive lamivudine monotherapy .</brief_summary>
	<brief_title>Continuing Lamivudine Versus Switching Entecavir Patients Who Achieved Undetectable HBV DNA</brief_title>
	<detailed_description>Entecavir high potent antiviral efficacy low drug resistance rate Lamivudine nucleoside-naïve CHB patient . The switch Lamivudine Entecavir patient undetectable hepatitis B virus DNA ( HBV DNA &lt; 60 IU/mL ) may lead prolonged viral suppression undetectable level PCR method , compare patient continuous lamivudine treatment . The result study provide rationale switch treatment one antiviral another one , especially LAM ETV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adult subject ( 1870 year age ) currently take lamivudine monotherapy chronic HBV infection least 6 month &lt; HBV DNA 60 IU/mL level HBeAg positive status . Subjects treat antiviral drug ( e.g . adefovir ) combination lamivudine eligible study . Subjects ALT ＜ 10 x ULN , evidence hepatocellular carcinoma . Subjects without serological evidence coinfection HCV , HIV , HDV . Subjects decompensated liver disease , well pregnant breastfeed woman , eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Entecavir</keyword>
</DOC>